In this article, we will discuss Anlotinib (Background-6). So, let’s get started.
Nevertheless, considering the unsatisfactory efficacies and limitations of current therapies for the different stages of many cancers, there is still a need to develop innovative, more effective, and safer anticancer drugs. For example, there is currently no standard third-line treatment for advanced non-small-cell lung cancer (NSCLC). Moreover, although several targeted drugs, including olaratumab, pazopanib, sunitinib, and everolimus, are efficacious for STS according to the National Comprehensive Cancer Network (NCCN) and European guidelines, the current targeted-therapy drugs for non-gastrointestinal stromal tissue (GIST) STS are still limited.